louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05697042: Merging Yoga and Self-Management Skills for Symptoms of Long COVID
Official title: A Mobile Intervention Merging Yoga and Self-Management Skills (MY-Skills Mobile) for Individuals Experiencing Symptoms of Long COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Long COVID
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2023-01-25
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Long COVID patients experience high symptom burden for many months after initial infection of the COVID-19 virus. This study will investigate a mobile intervention Merging Yoga and Self-Management Skills (MY-Skills Mobile) as a complementary therapy for fatigue, pain, mood and quality of life in long COVID patients at the UCHealth Center for Integrative Medicine. The study aim is to assess the feasibility and acceptability of MY-Skills Mobile and research procedures including planned assessments.


Eligibility criteria: Inclusion Criteria:

* patients referred to the UC Health Integrated Medicine Clinic for long COVID
* community-dwelling
* speak English
* able to provide informed consent
* stand with or without an assistive device
* complete the Exercise Assessment and Screening for You (EASY) tool; potential participants will receive instructions about safe physical activity and/or to obtain physician approval prior to enrollment.

Participants will not be excluded due to limited technology access. We will loan tablets and hotspots to participants who do not have hardware or internet.

Exclusion Criteria:

* current yoga ≥120 minutes a week
* completed self-management education in the last year
* cognitive impairment limiting participation in decision making

Primary outcomes:
measure: Feasibility- Recruitment
timeFrame: Week 1
measure: Feasibility- Use
timeFrame: Week 8
measure: Feasibility- Attrition
timeFrame: Week 8
measure: Feasibility-Usability
timeFrame: Week 8
Secondary outcomes:
measure: Symptom Burden Scale for Long COVID
timeFrame: Week 8
measure: PROMIS Fatigue
timeFrame: Week 8
measure: Brief Pain Inventory
timeFrame: Week 8
measure: Short Form 36
timeFrame: Week 8
Other outcomes:
Locations:
city: Aurora
country: United States
facility: UCHealth
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Jennifer Portz, PhD, MSW
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04189042: Figure-of-Eight Walk Test in Parkinson
Official title: Assessing Validity and Reliability of Figure-of-Eight Walk Test in People With Parkinson's Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Parkinson Disease
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2019-12-06
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with Parkinson's Disease who apply to the Gazi University, Department of Physiotherapy and Rehabilitation will be invited to this study.

Brief summary: The aim of study is to assess validity and reliability of Figure-of-Eight Walk Test in people with Parkinson's Disease


Eligibility criteria: Inclusion Criteria:

* at least 40 years of age
* neurologist-diagnosed Parkinson's Disease
* Hoehn \& Yahr (H\&Y) stages 1 to 3
* able to walk at least 20 meters

Exclusion Criteria:

* other neurologic disorder
* visual, auditory, orientational problems that could affect study results
* any orthopedic problem that prevents walking and standing
* have a cardiovascular, pulmonary or hormonal disorder

Primary outcomes:
measure: Figure-of-Eight Walk Test
timeFrame: 10-15 seconds
Secondary outcomes:
measure: Unified Parkinson's Disease Rating Scale
timeFrame: 15 minutes
measure: Hoehn and Yahr Scale
timeFrame: 1 minutes
measure: Timed Up and Go Test
timeFrame: 10-15 seconds
measure: Berg Balance Scale
timeFrame: 10-15 minutes
measure: 10 Meter Walk Test
timeFrame: 10-15 seconds
measure: Activities-Specific Balance Confidence (ABC) Scale
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University, Faculty of Health Sciences
Study officials:
References:
Clinical trial NCT04070742: Dermal Phototoxicity Study
Official title: A 4-Day, Randomized, Controlled Study to Evaluate the Phototoxicity Potential of FMX-101, 4% in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Vyne Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2019-08-28
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Dermal Safety study to determine the Phototoxicity Potential of FMX-101 4% in Healthy Volunteers


Eligibility criteria: Inclusion Criteria:

1. Healthy male or female volunteers age 18 years or older
2. Has uniformly-colored skin on the lower thoracic area of the back which allowed discernment of erythema, and were Fitzpatrick Skin Types I, II, or III

Exclusion Criteria:

1. Has any visible disease at the application site which, in the opinion of the investigative personnel, would have interfered with the evaluation of the test site reaction
2. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study

Primary outcomes:
measure: Comparison between Test and Vehicle sites of the post-irradiation erythema severity at 96 hours post-application using a dermal response numerical equivalent score
timeFrame: 4 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06513442: The Added Value of Bone Microstructure Assessment in the Management of Osteoporotic Bone
Official title: The Added Value of Bone Microstructure Assessment in the Management of Osteoporotic Bone
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Osteoporosis
Lead sponsor: Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
Sponsor class: OTHER_GOV
First posted: 2024-07-22
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult female and male patients over the age of 18.

Brief summary: 1. To assess the clinical utility of trabecular bone score (TBS) on fracture risk prediction including the new version (TBS V4) and future TBS versions at the spine and hip.
2. To assess the clinical utility of TBS software as a potential treatment outcome: sensitivity to change over time and following osteoporosis therapy.
3. To compare TBS to other imaging modalities of bone structure such as quantitative computed tomography (QCT) in fracture risk prediction and response to osteoporosis therapy.


Eligibility criteria: Inclusion Criteria: Has had a DEXA scan

* Has had a DEXA scan

Exclusion Criteria:

* Unable to complete DEXA scan

Primary outcomes:
measure: To assess the newest version of TBS software on fracture prediction
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01071642: The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Pressure
Keywords: Change in eGFR from baseline to 72 hours following the exposure to the contrast.
Rate of eGFR decrease>25% from the baseline
Length of hospitalization.
Requirement of unplanned therapy for elevated blood pressure
Lead sponsor: Soroka University Medical Center
Sponsor class: OTHER
First posted: 2010-02-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.


Eligibility criteria: Inclusion Criteria:

* 1. Age\>18 years
* 2. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file)
* 3. Subjects planned to undergo non-emergent coronary angiography.
* 4. Signed informed consent

Exclusion Criteria:

* 1. eGFR\<30 ml/min at baseline
* 2. Chronic utilization of NSAIDS and Cox-2 selective inhibitors
* 3. Chronic treatment with mineralocorticosteroid receptor blocker
* 4. Systolic blood pressure\<90 mmHg
* 5. Planned staged (repeated) procedure within 48 hours
* 6. Administration of contrast within 14 days prior to the enrollment
* 7. contraindication to stop ACE-I or ARB'S

Primary outcomes:
measure: Change in eGFR from baseline to 48 hours following the exposure to the contrast.
timeFrame: 48 hours after exposure to the contrast
Secondary outcomes:
measure: 1. Rate of eGFR decrease>25% from the baseline, 2. Length of hospitalization,
timeFrame: 48-72 hours after exposure to contrast
Other outcomes:
Locations:
city: Bear Sheva
country: Israel
facility: Talya Wolak
Study officials:
References:
Clinical trial NCT00460642: GnRH Antagonist to Prepare Recipients for Embryo Transfer
Official title: Use of GnRH Antagonist (Cetrotide) Protocol, Instead of Agonist, to Prepare Recipients for Embryo Transfer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: Frozen embryo transfers (FET).
Egg donation (ED).
IVF.
ART.
Implantation.
GnRH antagonist.
Cetrotide.
Endometrial response.
Infertility treatments:
Transfer of embryos from egg donation (ED) to recipients.
Lead sponsor: Institute for Human Reproduction (IHR)
Sponsor class: OTHER
First posted: 2007-04-16
Enrollment: 130
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: 26% of all ART cycles performed in the USA in 2003 (CDC data) are frozen embryo transfers (FET) and transfer of embryos resulting from egg donation (ED) to recipients. The typical protocol used to prepare a recipient for ET involves GnRH agonist (Lupron, Tap Pharmaceuticals) to down regulate the patient. A GnRH antagonist, such as Cetrotide (EMD Serono), is comparable to GnRH agonist and FDA approved to prevent spontaneous ovulation with ART treatment, and its usage decreases significantly the number of injections that the patient receives with treatment. The working hypothesis for this study is that the GnRH antagonist (Cetrotide) can be used instead of an agonist to achieve effective down regulation in FET and ED cycles. Presumably, patients will prefer Cetrotide over Lupron because of the markedly fewer injections required.


Eligibility criteria: Inclusion Criteria:

* History of infertility before cryopreserving the embryos or inability to conceive from her own oocytes (based on age and/or a serum FSH \> 15 IU/L).
* Any patient desiring to become pregnant as a result of transferring frozen-thawed embryos generated using her own or donor oocytes.
* Subject is in good health as determined by the Investigator on the basis of medical history, physical examination and laboratory screening tests.
* A negative pregnancy test prior to starting treatment with estrogens.

Exclusion Criteria:

* Women with a history of liver and/or kidney disease
* Hypertension: systolic pressure over 180 mm Hg or diastolic pressure over 105 at any study visit, measured twice 6 hours apart despite active treatment for hypertension.
* Liver function tests of two times than the upper limit of normal
* Women with active sever endometriosis.

Primary outcomes:
measure: Clinical Pregnancy Rate
Secondary outcomes:
measure: Delivery Rate
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Institute for Human Reproduction (IHR)
state: Illinois
city: Oakbrook Terrace
country: United States
facility: Institute for Human Reproduction (IHR)
state: Illinois
Study officials:
affiliation: President and Medical Director, Institute for Human Reproduction (IHR) and Director, Clinical IVF-PGD Program, Reproductive Genetics Institute (RGI).
name: Ilan Tur-Kaspa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06761742: Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests
Official title: An Artificial Intelligence Model for Accurate Diagnosis of Renal Tumors Based on Multi-phase Contrast-enhanced CT and Laboratory Tests: A Model Development and Multi-center Evaluation Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Tumors
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
Collaborators: name: Shanghai Jiao Tong University Affiliated Sixth People's Hospital
name: Fudan University Pudong Medical Center
name: Fudan University
name: The Affiliated Hospital Of Southwest Medical University
First posted: 2025-01-07
Enrollment: 1922
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consists of patients who underwent renal tumor resection at multiple centers, with complete preoperative imaging and laboratory data. Eligible participants include those with pathological diagnoses of clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal angiomyolipoma, or renal oncocytoma. Patients with incomplete imaging data, poor-quality CT images, or coexistence of multiple pathological types of renal tumors were excluded.

Brief summary: This multi-center retrospective study aims to develop a multimodal artificial intelligence diagnostic model using preoperative contrast-enhanced CT images and routine laboratory parameters from patients with renal tumors. The model is designed to assist clinicians in accurately predicting the pathological subtypes of renal tumors preoperatively, enabling detailed diagnoses and advancing precision medicine.


Eligibility criteria: Inclusion Criteria:

* Underwent renal tumor resection with a complete postoperative pathological report, and the pathological diagnosis is one of the following types: clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal angiomyolipoma, or renal oncocytoma.
* Complete and available four-phase contrast-enhanced CT scans prior to surgery.
* Complete and available routine laboratory test results prior to surgery.

Exclusion Criteria:

* Incomplete CT data or poor image quality that affects diagnostic analysis.
* A time interval of more than three months between imaging or laboratory testing and pathological diagnosis.
* Patients diagnosed with fat-rich renal angiomyolipoma (AML).
* Pathological diagnosis indicating the coexistence of two or more pathological types of renal tumors.

Primary outcomes:
measure: postoperative pathological report
timeFrame: From the time of surgery to the release of the postoperative pathological report (typically within 2 weeks post-surgery).
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Jiaotong University School of Medicine, Renji Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT04905342: NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers
Official title: An Open-label, Randomized, Evaluate the Pharmacokinetics and the Safety of NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: NVP Healthcare
Sponsor class: INDUSTRY
First posted: 2021-05-27
Enrollment: 58
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: single-dose, crossover study
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2.

Detailed description: Evaluate pharmacokinetics and safety of NVP-1805 compared to coadministration of NVP-1805-R1 with NVP-1805-R2

Eligibility criteria: Inclusion Criteria:

* Healthy adult subjects who signed informed consent
* BMI of \>18.0 kg/㎡ and \<30.0 kg/㎡ subject, weight more than 50kg(45 kg or more for woman)

Exclusion Criteria:

* Subjects participated in another clinical trial within 6 months prior to administration of the study drug
* Inadequate subject for the clinical trial by the investigator's decision
* Subjects participated in another clinical trial within 6 months prior to administration of the study drug

Primary outcomes:
measure: Pharmacokinetics of plasma: AUClast
timeFrame: 0hours - 72hours
measure: Pharmacokinetics of plasma: Cmax
timeFrame: 0hours - 72hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: H Plus Yangji Hospital
state: Nambusunhwan-ro
Study officials:
affiliation: H Plus Yangji Hospital
name: Jaewoo Kim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00958542: Prospective Study of Cerebral Palsy Scoliosis
Official title: Prospective Study of Scoliosis in Children With Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Cerebral Palsy
Scoliosis
Keywords: cerebral palsy
scoliosis
children
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2009-08-13
Enrollment: 45
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective, multi-centre study that will be looking at two groups of males and females over the course of their operative treatment for cerebral palsy (CP) scoliosis and the years following that treatment. The first group the study will be looking at is those individuals who undergo surgery for CP Scoliosis. The second group will be those individuals who do not undergo surgical treatment for CP Scoliosis, either because the family declines surgery or surgery is not recommended during the course of study participation.


Eligibility criteria: Inclusion Criteria:

* Between the ages of 8 and 18 years
* Diagnosis of Cerebral Palsy with total body involvement
* Coronal curve greater than 40 degrees OR a kyphotic curve greater than 50 degrees on sitting film will be included
* Growing rod treatment will also be included

Exclusion Criteria:

* Previous operated scoliotic spine deformity
* Diagnosis of Rett's Syndrome
* Concomitant lower extremity surgery (within 3 months of spinal fusion)
* Cornelia de Lange Syndrome or any pervasive genetic disorder whose effects are due to much more than the static cortical injury
* Ambulatory spastic diplegic without upper extremity impairment or speech, swallowing or other involvement

Primary outcomes:
measure: Comparison of pre- and post- operative x-rays
timeFrame: 1 year
Secondary outcomes:
measure: Gross motor function, physical data, past medical history, seizure status, pain and medications, sitting ability, activity level, clinical photos, quality of life questionnaires, data regarding surgery and hospital stay
timeFrame: 1 year
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Children's Hospital, Department of Orthopaedics
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Firoz Miyanji, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05910242: Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH)
Official title: Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Essential Hypertension
Lead sponsor: The First Hospital of Jilin University
Sponsor class: OTHER
First posted: 2023-06-18
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension.

Detailed description: Current studies have shown that remote ischemic conditioning can improve vascular endothelial function, inhibit sympathetic nervous system activity and regulate immune and inflammatory reactions. Thus it may exert anti-hypertensive effects through multiple mechanisms. The purpose of this study is to investigate the efficacy and safety of remote ischemic conditioning on blood pressure patients with essential hypertension.

Eligibility criteria: Inclusion Criteria:

1. Age≥18 years, regardless of sex;
2. Patients with systolic blood pressure ≥140mmHg with or without taking oral antihypertensive drugs
3. Signed and dated informed consent is obtained

Exclusion Criteria:

1. Secondary hypertension;
2. Clinical blood pressure ≥ 180/110 mmHg or 24-hour mean arterial pressure ≥ 170/100 mmHg;
3. Severe organ dysfunction or failure;
4. Severe hematologic disorders or significant coagulation abnormalities;
5. History of atrial fibrillation or myocardial infarction within 6 months;
6. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
7. Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc; ;
8. Pregnant or lactating women;
9. Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;
10. Other conditions that the researchers think are not suitable for the project.

Primary outcomes:
measure: Mean systolic blood pressure
timeFrame: 1-7 days
Secondary outcomes:
measure: Mean diastolic blood pressure
timeFrame: 1-7 days
Other outcomes:
Locations:
city: Changchun
country: China
facility: The First Hospital of Jilin University
state: Jilin
Study officials:
References: